Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes

Literals

ou:tipoPublicacion
- Article
vivo:identifier
- 2001-103
bibo:doi
- 10.1097/00007691-200112000-00004
fabio:hasPublicationYear
- 2001
dcterms:creator
- Llerena A.
ou:bibtex
- @article{RID:0916141122196-39, title = {Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes}, journal = {Therapeutic Drug Monitoring}, year = {2001}, author = {Llerena, A and Berecz, R and de la Rubia, A and Fernandez-Salguero, P and Dorado, P}, volume = {23}, number = {6}, pages = {616-620} }
dcterms:contributor
- Llerena, A; Berecz, R; de la Rubia, A; Fernandez-Salguero, P; Dorado, P
ou:eid
- 2-s2.0-0035187486
bibo:issn
- 0163-4356
bibo:page_range
- 616-620
dcterms:publisher
- Therapeutic Drug Monitoring
dcterms:title
- Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes
vcard:url
- https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0035187486&origin=inward
ou:urlOrcid
- http://europepmc.org/abstract/med/11802093
ou:urlScopus
- https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0035187486&origin=inward
ou:vecesCitado
- 49
bibo:volume
- 23